Fluor Builds Diabetes API Manufacturing Facility for Novo Nordisk

December 21, 2016
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 12, Issue 1

The $2-billion facility will be located in Clayton, North Carolina.

Fluor announced on Dec. 20, 2016 that it had been awarded an engineering, procurement, construction, and construction management contract by Novo Nordisk to build a new $2-billion 830,00-sq.-ft. diabetes API manufacturing facility in Clayton, North Carolina. Construction on the new facility is expected to be completed in mid-2019.

“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business, in a press release. “This project is the single largest life-sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”

“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry, and ability to deliver the full scope of work,” said Morten Nielsen, senior vice-president, Novo Nordisk, and responsible for the construction of the new facility, in the press release. “We look forward to continued strong cooperation for the success of this project.”

Source: Fluor